Dermira Inc. increased the size of its board to 10 directors from nine and elected Emmanuel Caeymaex as a class II director, effective Jan. 1, 2017.

UCB Pharma SA, which is entitled to designate one member to Dermira's board as part of a development and commercialization agreement, designated Caeymaex as its new designee to the board to replace Mark McDade.

Caeymaex is the executive vice president of immunology and patient value unit head of UCB Pharma's parent UCB SA. McDade, formerly an executive vice president and COO of UCB SA, was the previous designee under the agreement.